Predictive biomarkers along gastric cancer pathogenetic pathways (Q39170872)

9 September 2017

Predictive biomarkers along gastric cancer pathogenetic pathways (English)

1 reference

9 September 2017

0 references

0 references

7

Federica Zito Marino

1 reference

9 September 2017

Roberto Alfano

5

1 reference

ORCID Public Data File 2021

author name string

Iacopo Panarese

1

1 reference

9 September 2017

Ferdinando De Vita

2

1 reference

9 September 2017

Andrea Ronchi

3

1 reference

9 September 2017

Marco Romano

4

1 reference

9 September 2017

Natale Di Martino

6

1 reference

9 September 2017

Francesca Ferraraccio

8

1 reference

9 September 2017

Renato Franco

9

1 reference

9 September 2017

1 March 2017

1 reference

Expert Review of Anticancer Therapy

9 September 2017

1 reference

9 September 2017

17

1 reference

9 September 2017

5

1 reference

9 September 2017

417-425

1 reference

9 September 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Pathology of gastric cancer and its precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Recent patterns in gastric cancer: a global overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Comprehensive molecular characterization of gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Prognostic indicators in node-negative advanced gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Spectrum of Epstein-Barr virus-related diseases: a pictorial review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Tumours with PI3K activation are resistant to dietary restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Up-regulation of PIK3CA promotes metastasis in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Structure and function of the components of the human DNA mismatch repair system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

DNA repair dysfunction in gastrointestinal tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Microsatellite instability in gastrointestinal tract cancers: a brief update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Microsatellite instability is associated with the clinicopathologic features of gastric cancer in sporadic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Chemosensitivity and survival in gastric cancer patients with microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Emerging molecular classifications and therapeutic implications for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

The cell-cell adhesion molecule E-cadherin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Beyond E-cadherin: roles of other cadherin superfamily members in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

E-cadherin germline mutations in familial gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Aurora kinase A in gastrointestinal cancers: time to target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Polo-like kinases and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Molecular targeted therapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

The ErbB receptors and their ligands in cancer: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

HER2 testing in gastric cancer: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Basic and therapeutic aspects of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Crosstalk in Met receptor oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Increasing trends in Schedule II opioid use and doctor shopping during 1999-2007 in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

MET expression and amplification in patients with localized gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1301207

10.1080/14737140.2017.1301207

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference